SpringerLink
Log in

Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia

  • Letter to the Editor
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (France)

Instant access to the full article PDF.

Institutional subscriptions

Figure 1
Figure 2

References

  1. Buchner T, Berdel WE, Haferlach C, Haferlach T, Schnittger S, Muller-Tidow C et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol 2009; 27: 61–69.

    Article  Google Scholar 

  2. Gale RP, Cline MJ . High remission-induction rate in acute myeloid leukaemia. Lancet 1977; 1: 497–499.

    Article  CAS  Google Scholar 

  3. Stelljes M, Krug U, Beelen DW, Braess J, Sauerland MC, Heineke A et al. Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis. J Clin Oncol 2014; 32: 288–296.

    Article  Google Scholar 

  4. Buchner T, Berdel WE, Hiddemann W . Priming with granulocyte colony-stimulating factor—relation to high-dose cytarabine in acute myeloid leukemia. N Engl J Med 2004; 350: 2215–2216.

    Article  Google Scholar 

  5. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453–474.

    Article  Google Scholar 

  6. Falini B, Macijewski K, Weiss T, Bacher U, Schnittger S, Kern W et al. Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1). Blood 2010; 115: 3776–3786.

    Article  CAS  Google Scholar 

  7. Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996; 10: 1911–1918.

    CAS  Google Scholar 

  8. Pabst T, Mueller BU, Zhang P, Radomska HS, Narravula S, Schnittger S et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet 2010; 27: 263–270.

    Article  Google Scholar 

  9. Rosthoj S, Andersen PK, Abildstrom SZ . SAS macros for estimation of the cumulative incidence functions based on a Cox regression model for competing risks survival data. Comput Methods Prog Biomed 2004; 74: 69–75.

    Article  Google Scholar 

  10. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21: 4642–4649.

    Article  Google Scholar 

  11. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer Leukemia Group B. N Engl J Med 1994; 331: 896–903.

    Article  CAS  Google Scholar 

  12. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE et al. Age and acute myeloid leukemia. Blood 2006; 107: 3481–3485.

    Article  CAS  Google Scholar 

  13. Wheatley K, Brookes CL, Howman AJ, Goldstone AH, Milligan DW, Pentice AG et al. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br J Haematol 2009; 145: 598–605.

    Article  Google Scholar 

  14. Mrozek K, Marcucci G, Nicolet D, Maharry KS, Becker H, Whitman S et al. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol 2012; 30: 4515–4523.

    Article  Google Scholar 

  15. Buchner T, Berdel WE, Woermann BJ, Sauerland MC, Heinecke A, Krug U et al. Upfront randomization 10 years later: The AML Cooperative Group Strategy. Blood 2014; 124: 2267.

    Google Scholar 

Download references

Acknowledgements

Ms Birgit Mayerhoffer and Sabine Jacob helped to prepare the typescript. RPG acknowledges support from the National Institute of Health Research (NIHR) Biomedical Research Centre funding scheme.

Author information

Authors and Affiliations

  1. Department of Medicine A, Hematology, Oncology and Pneumology, University of Münster, Münster, Germany

    T Büchner, C Müller-Tidow, M Stelljes, R M Mesters & W E Berdel

  2. Department of Hematology and Oncology, Klinikum Leverkusen,

    U O Krug

  3. Leverkusen, Germany

    U O Krug

  4. Division of Experimental Medicine, Department of Medicine, Haematology Research Centre, Imperial College London, London, UK

    R Peter Gale

  5. Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany

    A Heinecke, M C Sauerland, D Görlich, A Faldum & W Köpcke

  6. MLL Munich Leukemia Laboratory, Munich, Germany

    C Haferlach, S Schnittger & T Haferlach

  7. Department of Hematology and Oncology, University of Frankfurt, Germany

    H L Serve

  8. Department of Hematology and Oncology, Krankenhaus Barmherzige Brüder, Regensburg, Germany

    J Braess

  9. Department of Internal Medicine III, University Hospital Munich, Grosshadern, Munich, Germany

    K Spiekermann & W Hiddemann

  10. Department of Hematology and Oncology, St -Antonius Hospital, Eschweiler, Germany

    P Staib

  11. Department of Hematology and Oncology, Vivantes Clinic Neukölln, Berlin, Germany

    A Grüneisen

  12. Department of Hematology and Oncology, University Regensburg, Regensburg, Germany

    A Reichle

  13. Department of Hematology and Oncology, Evangelisches Krankenhaus, Hamm, Germany

    L Balleisen

  14. Department of Hematology and Oncology, KKH St Marien Hospital, Hagen, Germany

    H Eimermacher

  15. Marienhospital Düsseldorf, Clinic for Oncology, Hematology and Palliative Care, Düsseldorf, Germany

    A Giagounidis

  16. Department of Hematology and Oncology, Klinikum Bremen-Mitte, Bremen, Germany

    H Rasche

  17. Department of Hematology and Oncology, University of Heidelberg, Mannheim, Germany

    E Lengfelder & R Hehlmann

  18. German Society of Hematology and Oncology, Berlin, Germany

    B J Wörmann

Authors
  1. T Büchner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. U O Krug
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R Peter Gale
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Heinecke
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M C Sauerland
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C Haferlach
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S Schnittger
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. T Haferlach
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. C Müller-Tidow
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M Stelljes
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. R M Mesters
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. H L Serve
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. J Braess
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. K Spiekermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. P Staib
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. A Grüneisen
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. A Reichle
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. L Balleisen
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. H Eimermacher
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. A Giagounidis
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. H Rasche
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. E Lengfelder
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. D Görlich
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. A Faldum
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. W Köpcke
    View author publications

    You can also search for this author in PubMed Google Scholar

  26. R Hehlmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  27. B J Wörmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  28. W E Berdel
    View author publications

    You can also search for this author in PubMed Google Scholar

  29. W Hiddemann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T Büchner.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Büchner, T., Krug, U., Peter Gale, R. et al. Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia. Leukemia 30, 1781–1784 (2016). https://doi.org/10.1038/leu.2016.54

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2016.54

  • Springer Nature Limited

This article is cited by

Search

Navigation